It is proposed to study 177LU-PSMA, a theory limited to radiological therapy that can be used to diagnose and treat metastatic Castration-Resistant Prostate Cancer (MCRPC). This therapy method has been proven effective and safe, although its feasibility and efficacy to manage the underlying condition are unknown. Tumor lesions, the heterogenic nature of LU-PSMA, unparalleled DNA configuration, and accelerated repopulation. LU-PSMA is highly appreciated by the patients and causes positive customer satisfaction (Gafita et al., 2020). MCRPC is a deleterious mutation that requires a more tailored therapeutic approach to achieve the desired medical outcomes.
Intense genetic breaks that are difficult to repair require concomitant medication. For example, Lutetium is combined with 177-PSMA-617 I to form Lutetium-177-617 for standard care therapies. PSMA is a long-term clinical condition whose changes in management are observed after six weeks (Gafita et al., 2020). Therefore, long-term follow-up with a median duration of about 21.5 months is vital to assert the performance of 177-PSMA-617 to improve patient outcomes. More clinical trials are necessary to define the efficacy of PSMA treatment and develop more concomitant medication.
The research articles relevant to the proposal include the study by Cao et al. (2021) indicated a remarkably prolonged Oculus Sinister (OS) in the long term after applying concomitant medication. Also, Gafia et al. (2020) found that PSMA is a long-term clinical condition whose changes in management are observed after six weeks. The study by Sun et al. (2021) is also relevant as the scholars concluded that the PSMA protein stimulates the development of cancer cells, which prompts further research regarding the efficacy of 177Lu-PSMA radioligand therapy.
References
Cao, J., Chen, Y., Hu, M., Zhang, W. (2021). 177lu-psma-rlt of metastatic castration-resistant prostate cancer: Limitations and improvements. Annals of Nuclear Medicine, 35, 861-870.
Gafita, A., Heck, M. M., Rauscher, I., Tauber, R., Cala, L., Franz, C., D’Alessandria, C., Retz, M., Weber, W. A., Eiber, M. (2020). Early prostate-specific antigen changes and clinical outcome after 177lu-psma radionuclide treatment in patients with metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine, 61, 1476-1483.
Sun, M., Niaz, M. J., Niaz, M. O., Tagawa, S. T. (2021). Prostate-specific membrane antigen (psma)-targeted radionuclide therapies for prostate cancer. Current Oncology Reports, 23, 59